Personalis, Inc., a leader in advanced genomics for cancer, announced that the company will present one oral presentation and five posters at the American Association for Cancer Research Annual Meeting being held this year in Atlanta, GA from March 31 – April 3, 2019.
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present one oral presentation and five posters at the American Association for Cancer Research (AACR) Annual Meeting being held this year in Atlanta, GA from March 31 – April 3, 2019.
Personalis presentations will highlight how fundamental oncology research informs the ongoing evolution of our leading immunogenomics analysis platform. The presentations will also detail the alignment between our genomics solutions and AACR’s 2019 theme: Integrative Cancer Science • Global Impact • Individualized Patient Care.
Following is a list of abstracts that will be presented at the meeting.
| Presentation # | Title & Presenter | Day & Time | Location | |||
| MS.BSB01.01 905 (Oral Presentation) | March 31 3:05 pm-3:20 pm | Room B206 | ||||
| PO.MCB09.04 2512 / 8 | April 1 1-5pm | Poster section 33 | ||||
| PO.BSB01.01 3377/8 | T-cell receptor repertoire profiling using an augmented transcriptome | April 2 8 am-12 pm | Poster section 31 | |||
| PO.TB11.02 3788 / 5 | Sensitive detection of oncoviruses integrated into a comprehensive tumor immuno-genomics platform | April 2 1 pm-5 pm | Poster section 8 | |||
| PO.CH03.01 4536 / 9 | April 3 8 am-12 pm | Poster section 2 | ||||
| PO.TB10.03 4695 / 8 | Development and Validation of an Accurate Exome-Scale cfDNA Detection Platform | April 3 8 am-12 pm | Poster section 9 |
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
View source version on businesswire.com: https://www.businesswire.com/news/home/20190331005042/en/
Contacts
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300
Source: Personalis, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20190331005042/en
